Open
專注於研發(fā)針對非腫瘤疾病，特別是心血管與自體免疫疾病的工程化細(xì)胞療法。技術(shù)平臺主要強化細(xì)胞的增殖和分泌功能，並且能精確篩選具潛力的細(xì)胞以確保其品質(zhì)。
Phibio is a U.S. biotech firm developing engineered cell therapies for cardiovascular and autoimmune diseases. We enhance cell proliferation and secretion, ensuring cell quality through precise screening. With diverse expertise in bioengineering, drug development, and clinical trials, our mission is to deliver safer, more effective cell therapies for global healthcare.
Phibio is a U.S. biotech firm developing engineered cell therapies for cardiovascular and autoimmune diseases. We enhance cell proliferation and secretion, ensuring cell quality through precise screening. With diverse expertise in bioengineering, drug development, and clinical trials, our mission is to deliver safer, more effective cell therapies for global healthcare.